following close on aimovig's heels are three other drugs that target cgrp: fremanezumab, galcanezumab, and eptinezumab (which is given by iv).
.
"the drug must be administered at the right time point during development," he said.
.
"we are calling for the immediate implementation of a statutory duty of candour for the health trusts."
.
shocking figures uncovered by labour show some patients are suffering agonising waits of as many as 541 days to begin treatment
.
.